The first clinical results from Pfizer and Moderna, with 95% efficacy, are figures that represent “good omens” for the rest of the pharmaceutical companies focused on the same protein.
As reported by the Johnson & Johnson executive, the pharmaceutical company has worked in the supply chain to be able to offer 1 billion vaccines in 2021 through a collaborative network.
“During the next six months there will be good news, we can see how these effective vaccines will be available to the public,” said Duato, who took the opportunity to emphasize that the vaccine his team works on will also guarantee “quality and safety standards” announced by other companies in the sector.
The speaker applauded the collaboration between partners in the pharmaceutical industry to find a vaccine: “It is not a competitive situation, it is a social issue and a global crisis in which we will need several vaccines, not just one, because we must vaccinate millions of people “.
To guarantee the vaccination of the population, Johnson & Johnson works together with governments on access and distribution plans, such as COVAX, a project to which they will allocate 500 million doses of their production for the lowest-income countries.
From the multinational they assure that the price will not focus on profit: “We will seek to guarantee access to the vaccine in all territories, the price will not be more than 10 dollars per vaccine.”